Amendment 1 RFP 75N93022R00034.pdf

AMENDMENT #1 RFP No. 75N93022R00034 1

Amendment No. 1 RFP No. 75N93022R00034

“External Quality Assurance Program Oversight Laboratory”

Solicitation Number: 75N93022R00034

Amendment Number: One (1)

Amendment Issue Date: May 4, 2023

Proposal Due Date/Time: June 21, 2023 at 3:00 PM, EST (Unchanged)

Issued By: Robert Corno

Contracting Officer

OA/DEA/NIAID/NIH/DHHS

5601 Fishers Lane, Room 3D10, MSC 9821 Bethesda, Maryland 20892-9821

Points of Contact: PRIMARY cornorj@niaid.nih.gov Robert Corno, Contracting Officer Phone: 240.669.5151

SECONDARY

chris.ray@nih.gov Chris Ray, Contract Specialist Phone: 240.627.3365

Please note that we do NOT intend to extend the due date for submission of proposals as a result of this amendment. The date specified for receipt of proposals remains unchanged.

Offerors must acknowledge receipt of this Amendment by identifying the amendment number and the date of the amendment on each copy of the submitted proposal. Failure to receive your acknowledgement may result in the rejection of your proposal. Except as provided herein, all terms and conditions of the solicitation remain unchanged and in full force and effect.

The purpose of this Amendment is to: (1) provide responses to questions from potential offerors, regarding the solicitation.

RESPONSES TO QUESTIONS FROM POTENTIAL OFFERORS:

mailto:cornorj@niaid.nih.gov mailto:chris.ray@nih.gov

AMENDMENT #1 RFP No. 75N93022R00034 2

Question 1 On Pg 169, there are two different assumptions listed for the Multiplex Program. Is the following assumption the correct one to use:

“The offeror shall assume that twice each year twenty U.S laboratories and ten international laboratories will require kit production and shipments of reagents and supplies for testing”?

Response to Question 1 The assumption for the Multiplex Program should only read: “The offeror shall assume that twice each year twenty U.S laboratories and ten international laboratories will require kit production and shipments of reagents and supplies for testing.”

Question 2 Given that the Omics, SARS-CoV-2, and mucosal programs are described in the overall Statement of Work, but are not described in the initial task order, is it to be assumed that these programs will be accounted for in possible future task orders?

Response to Question 2 Programs not described under Task Order #1, but present in the overall Statement of Work might be solicited at a later date as a task order(s).

END OF AMENDMENT NO. 1, RFP No. 75N93022R00034